3 days popular7 days popular1 month popular3 months popular

Osteoporosis: Positive top-line results announced from open-label study of romosozumab compared with Teriparatide

UCB and Amgen have announced top-line results from the STRUCTURE trial (STudy evaluating effect of RomosozUmab Compared with Teriparatide in postmenopausal women with osteoporosis at high risk for fracture previously treated with bisphosphonatE therapy). The study (NCT01796301) met the primary endpoint, demonstrating a statistically significant difference in favor of romosozumab in the percent change of [...]